-- Event to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 9, 2018--
Exelixis, Inc. (NASDAQ: EXEL) today announced that the company, along
with its partner Ipsen, will host a live briefing event for the
financial community to discuss data presented at the 2018 American
Society of Clinical Oncology Gastrointestinal Cancers Symposium
(ASCO-GI). The webcast event will be held following the closing of the
ASCO-GI day's sessions on Friday, January 19, 2018, beginning at 9:30
p.m. EST / 6:30 p.m. PST (local San Francisco time).
During the briefing, Exelixis and Ipsen management, along with an
invited guest, will discuss and provide context for the cabozantinib
clinical data presented earlier that day at the Symposium. Exelixis
previously announced that detailed results from the CELESTIAL trial will
be the subject of a late-breaking oral presentation at ASCO-GI.
CELESTIAL is a randomized, double-blind, placebo-controlled study of
cabozantinib versus placebo in patients with advanced hepatocellular
carcinoma who have received prior treatment with sorafenib.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company's website at
least 15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the webcast.
Alternatively, please call 855-793-2457 (domestic) or 631-485-4921
(international) and provide the conference call passcode 2478857 to join
A webcast replay will be archived on www.exelixis.com
for one year. A telephone replay will also be available until 11:59 p.m.
EST on January 26, 2018. Access numbers for the telephone replay are:
855-859-2056 (domestic) and 404-537-3406 (international); the passcode
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring these medicines to
patients globally. We are steadfast in our commitment to prudently
reinvest in our business to maximize the potential of our pipeline. We
intend to supplement our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis recently earned a spot on
Deloitte's Technology Fast 500 list, a yearly award program honoring the
500 fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Exelixis and the Exelixis logo are registered U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180109005766/en/
Source: Exelixis, Inc.
EVP, Public Affairs and Investor
For Exelixis, Inc.